Refine by
Anxiety Depression Articles & Analysis
42 news found
While three quarters (75%) of employers feel their organisation acknowledges fertility treatment as a significant life event, only 27% of employees who have experienced fertility challenges agree.1 As a result, more than a fifth (22%) currently felt unsupported by their organisation, rising to 38% in Poland, and more than a third (36%) have felt pressure from their employer to be at work while ...
Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat various psychiatric disorders such as depression, anxiety, schizophrenia, and others. The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
These concerns include compromised memory as well as the correlation between anxiety and ...
Thanksgiving is a time when families gather around the table to give thanks for their blessings, share a delicious meal, and create memories. It’s a holiday that encourages us to reflect on what we are grateful for and appreciate the people and opportunities in our lives. While Thanksgiving is traditionally a family-centric holiday, it’s also an excellent opportunity for businesses to ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. ...
The Scientific Difference - based on pre-clinical trial results at Western University THC vs Mentabinol® For many users, THC causes: Memory impairment and possible long-term cognitive side effects, Depression-like and schizophrenia-related symptoms, Anxiety and hyperactive activity, Schizophrenia due to gene vulnerability. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction. ...
The PTR platform has the opportunity to be used for delivery of medications in other large markets, including anxiety (CTx-2103 in development), insomnia, depression, bipolar disorder, Parkinson’s disease, xerostomia (dry mouth), migraine, and hypothyroidism. ...
Key findings from the completed 30 mg cohort of the SHORELINE Study, other clinical data and health economics and outcomes research (HEOR), and patient survey data being presented include: In an analysis of patients in the 30 mg cohort of the SHORELINE Study with elevated anxiety (n=569) and without elevated anxiety (n=156), there was a mean reduction in the ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum bioavailability. ...
“Using this first-ever combined computational/data capability, pharmaceutical partners will be able to more efficiently and effectively develop new drugs to treat illnesses like depression, anxiety, bipolar disorder, Alzheimer’s, Parkinson’s, schizophrenia, epilepsy, anorexia, ADHD and ...
Important Safety Information In clinical trials conducted in patients with narcolepsy, the most frequent adverse drug reactions (ADRs) reported with pitolisant were insomnia (8.4%), headache (7.7%), nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness (1.4%), depression (1.3%), tremor (1.2%), sleep disorders (1.1%), fatigue (1.1%), vomiting (1.0%), ...
Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia. The agreement is the result of a close collaboration with Bayer, which will also ensure in both Countries a smooth transition of the assets without disruption in the market. ...
According to a Mashable article on a study of the efficacy of VR treatment for depression and anxiety, “This type of immersive therapy is a viable and potentially revolutionizing method to treat certain mental health conditions. ...
'The global COVID-19 pandemic has increased reports of anxiety, depression, and deaths by suicide around the world, including among children and teenagers," said psychiatrist Allen Tien, MD, MHS. mdlogix president and chief science officer. ...